Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

(2015) Srinivasan Dasarathy et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

‘Corrigendum to “Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease” [Contemp Clin Trials 37 (2) (2014) 301–311]’

(2014) E. Scorletti et al.   Contemporary Clinical Trials

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease

(2014) E. Scorletti et al.   Contemporary Clinical Trials

Role of Docosahexaenoic Acid Treatment in Improving Liver Histology in Pediatric Nonalcoholic Fatty Liver Disease

(2014) Valerio Nobili et al.   PLoS One

Omega-3 Fatty Acids, Hepatic Lipid Metabolism, and Nonalcoholic Fatty Liver Disease

(2013) E. Scorletti et al.   Annual Review of Nutrition

Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications

(2013) Giovanni Targher et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease

(2013) Kenneth Cusi et al.   JOURNAL OF HEPATOLOGY

Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish

(2012) Lucy M Browning et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

(2012) Lokpal S. Bhatia et al.   EUROPEAN HEART JOURNAL

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

(2012) Naga Chalasani et al.   GASTROENTEROLOGY

The epidemiology, pathogenesis and histopathology of fatty liver disease

(2012) Adam P Levene et al.   HISTOPATHOLOGY

Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2011) Helen M. Parker et al.   JOURNAL OF HEPATOLOGY

Low dietary fish-oil threshold for myocardial membrane n-3 PUFA enrichment independent of n-6 PUFA intake in rats

(2010) Emily L. Slee et al.   JOURNAL OF LIPID RESEARCH

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current patterns of diet in community-dwelling older men and women: results from the Hertfordshire Cohort Study

(2009) Siân Robinson et al.   AGE AND AGEING

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

(2009) Alexis St. George et al.   HEPATOLOGY

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

(2009) Vlad Ratziu et al.   HEPATOLOGY

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

(2009) Curtis K. Argo et al.   JOURNAL OF HEPATOLOGY

Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?

(2008) M. Dietrich et al.   ATHEROSCLEROSIS

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

(2008) Feng-Shang Zhu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

(2007) L. Spadaro et al.   DIGESTIVE AND LIVER DISEASE